A Randomized, placebo-controlled, phase 3 study of the safety and efficacy of solriamfetol (JZP-110) for the treatment of excessive sleepiness (ES) in participants with narcolepsy types 1 and 2 (NT1/2)

Authors
Category Primary study
JournalNeurology
Year 2018
This article has no abstract
Epistemonikos ID: a6c29d60e1dd7ac9e9013540356e5a0a16fb10ae
First added on: Feb 09, 2025